$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000147929020000058 Filed on May 07, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$58.00K	$278.0K
YoY Change	-79.14%	44.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$21.22M	$12.91M
YoY Change	64.4%	-5.19%
% of Gross Profit
Research & Development	$39.79M	$24.00M
YoY Change	65.84%	7.9%
% of Gross Profit
Depreciation & Amortization	$739.0K	$628.0K
YoY Change	17.68%	61.03%
% of Gross Profit
Operating Expenses	$61.02M	$36.91M
YoY Change	65.34%	2.93%
Operating Profit	-$60.96M	-$36.63M
YoY Change	66.43%	2.71%
Interest Expense	$2.148M	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$126.0K	-$155.0K
YoY Change	-18.71%	-51.41%
Pretax Income	-$61.83M	-$35.30M
YoY Change	75.16%	0.74%
Income Tax	$100.0K	$0.00
% Of Pretax Income
Net Earnings	-$61.93M	-$35.30M
YoY Change	75.43%	0.76%
Net Earnings / Revenue	-106781.03%	-12699.28%
Basic Earnings Per Share	-$1.15
Diluted Earnings Per Share	-$1.15	-$848.6K
COMMON SHARES
Basic Shares Outstanding	53.87M shares	44.03M shares
Diluted Shares Outstanding	53.87M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$511.3M	$271.0M
YoY Change	88.67%	0.82%
Cash & Equivalents	$286.6M	$65.27M
Short-Term Investments	$224.6M	$205.7M
Other Short-Term Assets	$7.200M	$6.100M
YoY Change	18.03%	32.61%
Inventory
Prepaid Expenses
Receivables		$0.00
Other Receivables		$0.00
Total Short-Term Assets	$518.4M	$277.1M
YoY Change	87.08%	1.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.97M	$15.38M
YoY Change	-9.18%	52.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.494M	$3.146M
YoY Change	-52.51%	338.16%
Total Long-Term Assets	$74.49M	$47.36M
YoY Change	57.28%	316.82%
TOTAL ASSETS
Total Short-Term Assets	$518.4M	$277.1M
Total Long-Term Assets	$74.49M	$47.36M
Total Assets	$592.9M	$324.5M
YoY Change	82.73%	13.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.709M	$4.486M
YoY Change	94.14%	-16.32%
Accrued Expenses	$16.18M	$13.52M
YoY Change	19.65%	21.59%
Deferred Revenue	$10.08M	$13.05M
YoY Change	-22.79%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$41.64M	$34.07M
YoY Change	22.2%	48.16%
LONG-TERM LIABILITIES
Long-Term Debt	$171.3M	$0.00
YoY Change
Other Long-Term Liabilities	$71.60M	$69.30M
YoY Change	3.32%	176.1%
Total Long-Term Liabilities	$242.9M	$69.30M
YoY Change	250.51%	176.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.64M	$34.07M
Total Long-Term Liabilities	$242.9M	$69.30M
Total Liabilities	$284.6M	$103.4M
YoY Change	175.27%	114.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$906.1M	-$720.1M
YoY Change	25.83%	24.76%
Common Stock	$1.214B	$941.1M
YoY Change	29.0%	15.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$308.4M	$221.1M
YoY Change
Total Liabilities & Shareholders Equity	$592.9M	$324.5M
YoY Change	82.73%	13.94%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$61.93M	-$35.30M
YoY Change	75.43%	0.76%
Depreciation, Depletion And Amortization	$739.0K	$628.0K
YoY Change	17.68%	61.03%
Cash From Operating Activities	-$43.29M	-$11.41M
YoY Change	279.26%	2.42%
INVESTING ACTIVITIES
Capital Expenditures	$539.0K	$1.084M
YoY Change	-50.28%	1.5%
Acquisitions
YoY Change
Other Investing Activities	-$104.9M	-$102.4M
YoY Change	2.5%	-48.63%
Cash From Investing Activities	-$105.6M	-$103.4M
YoY Change	2.06%	-48.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$264.3M	$106.9M
YoY Change	147.36%	-4909.54%
NET CHANGE
Cash From Operating Activities	-$43.29M	-$11.41M
Cash From Investing Activities	-$105.6M	-$103.4M
Cash From Financing Activities	$264.3M	$106.9M
Net Change In Cash	$115.5M	-$7.987M
YoY Change	-1545.96%	-96.26%
FREE CASH FLOW
Cash From Operating Activities	-$43.29M	-$11.41M
Capital Expenditures	$539.0K	$1.084M
Free Cash Flow	-$43.83M	-$12.50M
YoY Change	250.68%	2.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	rvnc	Equity Component Of Convertible Debt Transaction Cost EquityComponentOfConvertibleDebtTransactionCost	3583000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52374735	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57026154	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52374735	shares
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-36297
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0551645
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7555 Gateway Boulevard
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Newark
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94560
CY2020Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3042000	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2952000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	41635000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40979000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7171000	USD
CY2020Q1	dei	City Area Code CityAreaCode	510
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	742-3400
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2020Q1	dei	Trading Symbol TradingSymbol	RVNC
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57052046	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	286649000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171160000	USD
CY2020Q1	us-gaap	Short Term Investments ShortTermInvestments	224621000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	118955000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6487000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	518441000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	296602000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13967000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14755000	USD
CY2020Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	32334000	USD
CY2019Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	0	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	25961000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26531000	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	730000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	730000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1494000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1669000	USD
CY2020Q1	us-gaap	Assets Assets	592927000	USD
CY2019Q4	us-gaap	Assets Assets	340287000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8709000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8010000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16178000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18636000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10079000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7911000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3627000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3470000	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	57000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	52000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1213931000	USD
CY2020Q1	us-gaap	Senior Long Term Notes SeniorLongTermNotes	171305000	USD
CY2019Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	0	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	46722000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	47948000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24890000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25870000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	284552000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	114797000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1069639000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	524000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-906137000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-844204000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	308375000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	225490000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	592927000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	340287000	USD
CY2020Q1	us-gaap	Revenues Revenues	58000	USD
CY2019Q1	us-gaap	Revenues Revenues	278000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39794000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23995000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21224000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12910000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	61018000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	36905000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-60960000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-36627000	USD
CY2020Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1491000	USD
CY2019Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1570000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	2148000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q1	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-90000	USD
CY2019Q1	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-92000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-126000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-155000	USD
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57026154	shares
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	308375000	USD
CY2020Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-61833000	USD
CY2019Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-35304000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-61933000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.15
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53868036	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41598919	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44004658	shares
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	221103000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-35304000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	521000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	78000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61412000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35226000	USD
CY2020Q1	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-61933000	USD
CY2019Q1	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-35304000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-61933000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-35304000	USD
CY2020Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	11184000	USD
CY2019Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6544000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4159000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1505000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	739000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	628000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	513000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	649000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-371000	USD
CY2019Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-88000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-27000000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	467000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1018000	USD
CY2020Q1	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	-570000	USD
CY2019Q1	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	3440000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-175000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-101000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	789000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3736000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2373000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	54500000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2298000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	942000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-278000	USD
CY2020Q1	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	-822000	USD
CY2019Q1	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	3333000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43289000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11414000	USD
CY2020Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	159412000	USD
CY2019Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	127357000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	539000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1084000	USD
CY2020Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	118000	USD
CY2019Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2019Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	25000000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-105569000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-103441000	USD
CY2020Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	287500000	USD
CY2019Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020Q1	rvnc	Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount	15581000	USD
CY2019Q1	rvnc	Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount	108100000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	572000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18000	USD
CY2020Q1	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	28865000	USD
CY2019Q1	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	0	USD
CY2020Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	8703000	USD
CY2019Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1401000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1049000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	337000	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	201000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	264347000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	106868000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	115489000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7987000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171890000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73986000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	287379000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65999000	USD
CY2020Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	43400000	USD
CY2020Q1	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
CY2019Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2020Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	487000	USD
CY2019Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2020Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	247000	USD
CY2019Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	1108000	USD
CY2020Q1	rvnc	Noncash Deferred Offering Costs NoncashDeferredOfferingCosts	0	USD
CY2019Q1	rvnc	Noncash Deferred Offering Costs NoncashDeferredOfferingCosts	320000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-61900000	USD
CY2020Q1	rvnc	Working Capital Surplus WorkingCapitalSurplus	476800000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-906100000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	511300000	USD
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, revenue recognition, deferred revenue classification, accruals including clinical trial costs, stock-based compensation, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration of asset acquisitions, and accounting for income taxes. We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 has caused a global slowdown of economic activity which has decreased demand for a broad variety of goods and services, including from our potential customers, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. We are unable to predict the future effect resulting from the COVID-19 pandemic on, for instance, paused clinical trials and revised product launch timing. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.</span></div>
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3890000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	509109000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	524000	USD
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	31000000.0	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	509633000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	282683000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	282686000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	509633000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	282686000	USD
CY2020Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	11200000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2020Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P14Y
CY2019Q1	us-gaap	Lease Cost LeaseCost	1633000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1425000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1343000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	77000	USD
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	290000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	1502000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	5057000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6942000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5464000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5557000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5733000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	12226000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	40979000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12462000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	28517000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.120
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1677000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1450000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q1	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	28900000	USD
CY2020Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	643000	USD
CY2020Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1461000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	44000	USD
CY2020Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2148000	USD
CY2020Q1	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	28900000	USD
CY2020Q1	rvnc	Capped Calls Price Cap CappedCallsPriceCap	48.88
CY2020Q1	rvnc	Capped Calls Premium Percentage Over Sale Price CappedCallsPremiumPercentageOverSalePrice	1
CY2020Q1	rvnc	Capped Calls Number Of Shares Subject To Antidilution Adjustments CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments	8900000	shares
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6544000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4159000	USD
CY2020Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	229500000	USD
CY2020Q1	rvnc	Indemnification Liability Recordedduring Period IndemnificationLiabilityRecordedduringPeriod	0	USD

Files In Submission

Name	View Source	Status
0001479290-20-000058-index-headers.html	Edgar Link	pending
0001479290-20-000058-index.html	Edgar Link	pending
0001479290-20-000058.txt	Edgar Link	pending
0001479290-20-000058-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20200331.xsd	Edgar Link	pending
rvnc-20200331_cal.xml	Edgar Link	unprocessable
rvnc-20200331_def.xml	Edgar Link	unprocessable
rvnc-20200331_lab.xml	Edgar Link	unprocessable
rvnc-20200331_pre.xml	Edgar Link	unprocessable
rvnc-q120exhibit311.htm	Edgar Link	pending
rvnc-q120exhibit312.htm	Edgar Link	pending
rvnc-q120exhibit321.htm	Edgar Link	pending
rvnc-q120exhibit322.htm	Edgar Link	pending
rvncq12010-q.htm	Edgar Link	pending
rvncq12010-q_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2020 Q1 Form 10-Q Financial Statement

#000147929020000058 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2020 Q1 Form 10-Q Financial Statement

#000147929020000058 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc